北美甲氨蝶呤注射剂市场 – 行业趋势及 2029 年预测

市场定义和见解

甲氨蝶呤注射液单独使用或与其他药物一起使用，用于治疗各种类型的癌症，例如乳腺癌、头颈癌、肺癌、血癌、骨癌、淋巴结癌和子宫癌。

自身免疫性疾病的高发性、炎症性疾病患者数量的增加以及医疗支出的增加预计将推动北美甲氨蝶呤注射剂市场的增长。然而，癌症治疗替代品的存在预计将成为市场增长的制约因素。

甲氨蝶呤是一种癌症疗法，可阻止癌细胞复制。这有助于防止癌细胞繁殖并扩散到全身。在将甲氨蝶呤剂量调整到最大剂量后，可能需要长达 12 周的时间才能看到效果。自身免疫性疾病负担的增加和医疗支出的增加加速了对甲氨蝶呤注射剂的需求，推动了市场的增长。

然而，使用甲氨蝶呤的副作用和并发症阻碍了预测期内北美甲氨蝶呤注射剂市场的增长。

北美甲氨蝶呤注射剂市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析，北美甲氨蝶呤注射剂市场在 2022 年至 2029 年的预测期内将以 6.0% 的复合年增长率增长。

Methotrexate Injection Market Dynamics

Drivers

• Increased prevalence of cancer

The increasing patient population with breast cancer, lung cancer, head and neck cancer, and blood cancer is fuelling the growth of North America methotrexate injection market. Breast cancer is the most recurrent invasive cancer in women, and it is the second leading cause of death in women after lung cancer. The American Cancer Society estimates that 41,760 women have breast cancer. Breast cancer starts quite small, to be felt. As the growth continues, the tumor spreads to the breast and other parts of the body. It results in serious health issues and can cause death. 80% of lung cancer deaths are caused due to smoking and exposure to tobacco. Lung cancer exists as the leading cause of death, with an estimated 1.8 million deaths.

• Government initiatives to spread awareness about lung and breast cancer

Government initiatives refer to statements or programs which are necessitated to solve the problem. The government raises awareness or delivers better health and safety initiatives to treat breast cancer in women and lung cancer. It promotes partnerships among healthcare organizations, facilities and manufacturers to necessitate the therapy and treatment for breast cancer in women and lung cancer.

The initiatives conducted by the government will result in the safety of the patient, cost savings, and less surgical care impact. In addition, hospitals and healthcare organizations will profit by enforcing protocols by collaborating with government organizations for supply and delivery. The government has already started funding such work in a small way but believes that more needs to be done. Therefore, this feature is expected to supplement the growth of the North America methotrexate injection market.

Opportunity

•  Strategic initiatives by the market players

An increase in the burden of various types of cancers and thyroid nodules malignancy across the regions and the increase in the geriatric population has created more demand for diagnostic procedures for the timely treatment of patients. The main aim is to improve health management and diagnostics for quality performance before reaching the critical stages of the disease. Major market players focus on filling the demands of healthcare professionals and spending a quite noticeable amount for better products.

Major players are involved in making the strategies and implementing them, such as acquisition, and product launch.

Restraints/Challenges

Research and development are prerequisites for modifying the products of advanced nature. As the demand for diagnostic procedures for cancer increases, companies are investing more in research and development to offer the best diagnostic options for convenient patient outcomes.

Research laboratories are lately investing more in products and procedures due to rising cases of cancer and its requirement of early diagnosis to save the patient's life. Research and development have enhanced customization in diagnosis since all humans' cells and tissues are not the same.

The increasing tobacco consumption and the rising growing population have surged cancer cases globally. Thereby the demand for research and development in pharmaceutical industries for diagnosis of it is also getting hyped. Hence increasing research and development activities are anticipated to be a greater opportunity for North America methotrexate injection market.

Furthermore, the use of methotrexate across the globe is rapidly increasing, with the growth of the aged population and several carcinogenic diseases which are preventable by the early diagnosis. At the same time, the players of the methotrexate injection manufacturers in the market have to follow certain regulations to get approval from the upper authorities to launch the product in the market. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. The pre-market approval of various medical devices varies from one country to another. The Food and Drug Administration (FDA) regulate the U.S.

North America methotrexate injection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on North America methotrexate injection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In March 2022, Viatris Inc. and Kindeva Drug Delivery L.P. announced that Mylan Pharmaceuticals Inc., a Viatris subsidiary, had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca's Symbicort.
• 2022 年 1 月，专业制药公司 Cumberland Pharmaceuticals Inc. 签署并达成最终协议，从 Kyowa Kirin, Inc. 收购 FDA 批准的肿瘤支持治疗药物 SANCUSO。Kyowa Kirin, Inc. 是日本 Kyowa Kirin Co., Ltd. 的美国分公司，Kyowa Kirin Co., Ltd. 是一家专注于发现和提供新型药物的全球专业制药公司。这有助于该公司扩大业务。

北美甲氨蝶呤注射剂市场

北美甲氨蝶呤注射液市场根据产品、类型、可用性、剂型、应用、年龄组、给药途径、最终用户和分销渠道分为九个值得注意的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

• 按产品
  • 含防腐剂
  • 不含防腐剂

根据产品，北美甲氨蝶呤注射剂市场分为含防腐剂和不含防腐剂。

• 按类型
  • 自我注射解决方案
  • 静脉注射液

根据类型，北美甲氨蝶呤注射剂市场分为自注射溶液和静脉注射溶液

• 可用性
  • 25毫克/毫升
  • 50毫克/2毫升

根据供应情况，北美甲氨蝶呤注射剂市场细分为 25MG/ML 和 50MG/2ML

• 剂型
  • 解决方案
  • 粉末

根据剂量，北美甲氨蝶呤注射剂市场分为溶液和粉末

• 应用
  • 癌症
  • 自身免疫性疾病
  • 怀孕

根据应用，北美甲氨蝶呤注射剂市场分为癌症、自身免疫性疾病、怀孕。

• 年龄组
  • 儿科
  • 成年人
  • 老年

根据年龄组，北美甲氨蝶呤注射剂市场分为儿科、成人和老年病

• 给药途径
  • 肌肉注射
  • 静脉
  • 动脉内
  • 鞘内

根据给药途径，北美甲氨蝶呤注射市场细分为肌肉注射、静脉注射、动脉注射、鞘内注射

• 最终用户
  • 医院
  • 诊所
  •  家庭医疗保健
  • 其他的

根据最终用户，北美甲氨蝶呤注射剂市场细分为医院、诊所、家庭医疗保健和其他

• 分销渠道
  • 医院药房
  •  零售药店
  • 网上药店
  •  其他的

根据分销渠道，北美甲氨蝶呤注射剂市场分为医院药房、零售药房、网上药房和其他。

北美甲氨蝶呤注射剂市场区域分析/见解

对北美甲氨蝶呤注射剂市场进行了分析，并按国家、产品、类型、可用性、剂型、应用、年龄组、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

北美甲氨蝶呤注射剂市场报告涵盖的国家包括美国、加拿大和墨西哥。

由于美国拥有大量制造商，且该地区政府举措和组织不断增多，美国在北美甲氨蝶呤注射剂市场占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和甲氨蝶呤注射剂市场 份额分析

北美甲氨蝶呤注射液市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对甲氨蝶呤注射液市场的关注有关。

市场的主要参与者包括辉瑞公司、Antares Pharma 公司、Fresenius Kabi USA、Medexus Pharmaceuticals 公司、Viatris 公司、Sandoz AG（诺华公司的子公司）、Teva Pharmaceuticals USA 公司、Accord BioPharma、Hikma Pharmaceuticals PLC、Cumberland Pharmaceuticals 公司、PV Pharma 等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-68155